Q32 Bio (QTTB) director granted 53,521 options at $2.80, vesting by Oct 23, 2026

Rhea-AI Filing Summary

Q32 Bio (QTTB) reported a director stock option grant. On 10/23/2025, the reporting person received a stock option for 53,521 shares at an exercise price of $2.80 per share. Following the transaction, 53,521 derivative securities were beneficially owned directly.

The option vests in full upon the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service, and expires on 10/22/2035. The filing lists the grant as an acquisition.

Insights

Corporate governance analyst

Routine director option grant; administrative disclosure.

Q32 Bio reported a standard equity award to a director: an option for 53,521 shares at an exercise price of $2.80 granted on 10/23/2025. This is typical board compensation and is recorded as an acquisition (grant).

The option vests in full at the earlier of 10/23/2026 or the next annual meeting, contingent on continued service, and expires on 10/22/2035. Such terms are common and do not, by themselves, alter the company’s financial outlook.

Actual impact depends on future exercise decisions and market conditions; no cash proceeds occur until any exercise at $2.80 per share.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Manke Isaac

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	53,521	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 53,521 shares (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

FAQ

What did Q32 Bio (QTTB) disclose in this Form 4?

A director received a stock option grant for 53,521 shares at an exercise price of $2.80 on 10/23/2025.

What is the vesting schedule for the QTTB director’s option grant?

It vests in full upon the earlier of October 23, 2026 or the issuer’s next annual meeting, subject to continued service.

When does the Q32 Bio director option expire?

The option expires on 10/22/2035.

How many derivative securities are beneficially owned after the transaction?

The filing reports 53,521 derivative securities beneficially owned directly after the transaction.

What was the transaction code for the QTTB option grant?

The transaction was reported with code A, indicating an acquisition (grant).

Who benefits from cash if the option is exercised?

If exercised, the issuer would receive the $2.80 per-share exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/27/2025 - 09:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manke Isaac

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.8	10/23/2025		A		53,521		(1)	10/22/2035	Common Stock	53,521	$0.00	53,521	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Eric Bell, Attorney-in-Fact	10/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.